---
schema_version: "secwatch.filing_event.v1"
accession: "0000856982-23-000039"
form_type: "8-K"
ticker: "MMSI"
cik: "0000856982"
company_name: "MERIT MEDICAL SYSTEMS INC"
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:27:15.376654+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merit Medical acquires two product portfolios for $132.5M; updates 2023 guidance

## Summary
- Acquired dialysis catheter portfolio & BioSentry system from AngioDynamics for $100M cash.
- Acquired Surfacer Inside-Out Access Catheter System from Bluegrass Vascular for $32.5M cash.
- Projects combined acquisitions to add ~$30M annual revenue; accretive to non-GAAP net income and EPS in first full year.
- Reaffirms stand-alone FY2023 guidance; updated to include partial-year impact from acquisitions.
- Extended CEO Fred Lampropoulos employment through 12/31/2025; base salary increased to $1,890,000.

## SEC filing metadata
- accession: 0000856982-23-000039
- form_type: 8-K
- ticker: MMSI
- cik: 0000856982
- company_name: MERIT MEDICAL SYSTEMS INC
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/0000856982-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/mmsi-20230608x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000856982-23-000039
- JSON: https://secwatch.observer/filing/0000856982-23-000039.json
- Plain text: https://secwatch.observer/filing/0000856982-23-000039.txt

## Key facts
- Earnings Releases
  MERIT MEDICAL SYSTEMS INC updated its full-year 2023 guidance (reaffirmed).
  - Period: full-year 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year 2023 financial guidance to include partial-year impact from acquisitions
  evidence_url: https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/0000856982-23-000039-index.htm
- Material Agreements
  MERIT MEDICAL SYSTEMS INC entered into Purchase Agreement with AngioDynamics, Inc. valued at $100 million (effective 2023-06-08).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: AngioDynamics, Inc.
  - Value: $100 million
  - Effective: 2023-06-08
  source text: On June 8, 2023, Merit entered into an Asset Purchase Agreement (the “Purchase Agreement”) with AngioDynamics, Inc., a Delaware corporation (“AngioDynamics”), pursuant to which Merit acquired a portfolio of dialysis catheter products, including various assets related thereto, and the BioSentry ® Biopsy Tract Sealant System from AngioDynamics (collectively, the “Acquisition”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/0000856982-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.